Literature DB >> 9420310

Abnormal predominance of IgG in HIV-specific antibodies produced by short-term cultured duodenal biopsy specimens from HIV-infected patients.

T Schneider1, T Zippel, W Schmidt, G Pauli, W Heise, U Wahnschaffe, E O Riecken, M Zeitz, R Ullrich.   

Abstract

The aim of our study was to analyze HIV-specific humoral immunity in the intestinal mucosa at different stages of HIV infection in comparison with serum and saliva. Duodenal biopsy specimens from 30 AIDS patients and 9 HIV-infected patients without AIDS were cultured for 48 hours. Culture supernatants, as well as simultaneously obtained serum and saliva samples, were adjusted to the same immunoglobulin concentrations and tested for HIV-specific IgG and IgA by Western blot. The HIV antigen pattern differed clearly between IgA and IgG but was similar for each isotype independent of its origin (i.e., serum, saliva, or biopsy specimen supernatants). Short-term cultured duodenal biopsy specimens from HIV-infected patients at all stages produced predominantly IgG, which was broadly reactive with HIV antigens. Lower titers of HIV-specific IgA, which recognized few antigens, were found, mostly the glycoprotein gp160. At later stages of the disease compared with earlier stages, the reaction pattern of mucosal IgA from saliva and biopsy supernatants was even more restricted; secretory component was frequently absent. The abnormal predominance of HIV-specific IgG over IgA in mucosal secretions may result from abnormal antibody production in the mucosa rather than from serum leakage. Mucosal inflammation induced by HIV-IgG immune complexes and insufficient immune exclusion by secretory IgA may not only lead to increased mucosal HIV replication but may also contribute to gastrointestinal disease in HIV-infected patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9420310     DOI: 10.1097/00042560-199712150-00004

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  8 in total

1.  Purification and functional characterization of mucosal IgA from vaccinated and SIV-infected rhesus macaques.

Authors:  Thomas Musich; Thorsten Demberg; Ian L Morgan; Jacob D Estes; Genoveffa Franchini; Marjorie Robert-Guroff
Journal:  Clin Immunol       Date:  2015-04-01       Impact factor: 3.969

2.  Mucosal and systemic antibody responses in humans infected with simian foamy virus.

Authors:  James E Cummins; Roumiana S Boneva; William M Switzer; Logan L Christensen; Paul Sandstrom; Walid Heneine; Louisa E Chapman; Charlene S Dezzutti
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

3.  Lack of simian immunodeficiency virus (SIV) specific IgA response in the intestine of SIV infected rhesus macaques.

Authors:  F Schäfer; S Kewenig; N Stolte; C Stahl-Hennig; A Stallmach; F-J Kaup; M Zeitz; T Schneider
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

Review 4.  Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection.

Authors:  Zdenek Hel; Elizabeth Stringer; Jiri Mestecky
Journal:  Endocr Rev       Date:  2009-11-10       Impact factor: 19.871

5.  Mucosal immunity to HIV: a review of recent literature.

Authors:  Barbara L Shacklett
Journal:  Curr Opin HIV AIDS       Date:  2008-09       Impact factor: 4.283

6.  Intestinal B cell hyperactivity in AIDS is controlled by highly active antiretroviral therapy.

Authors:  D E Nilssen; O Øktedalen; P Brandtzaeg
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

7.  Intraepithelial γδ T cells remain increased in the duodenum of AIDS patients despite antiretroviral treatment.

Authors:  Dag E Nilssen; Per Brandtzaeg
Journal:  PLoS One       Date:  2012-01-04       Impact factor: 3.240

8.  Absence of epithelial immunoglobulin A transport, with increased mucosal leakiness, in polymeric immunoglobulin receptor/secretory component-deficient mice.

Authors:  F E Johansen; M Pekna; I N Norderhaug; B Haneberg; M A Hietala; P Krajci; C Betsholtz; P Brandtzaeg
Journal:  J Exp Med       Date:  1999-10-04       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.